Monte Rosa Therapeutics Inc (GLUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 12,768 | 23,194 | 84,929 | 60,647 | 9,216 |
| Gross Profit | 12,768 | 23,194 | 84,929 | 60,647 | 9,216 |
| Operating Expenses | 45,743 | 38,748 | 40,893 | 47,643 | 35,743 |
| Operating Income | -32,975 | -15,554 | 44,036 | 13,004 | -26,527 |
| Other Income | 2,717 | 4,458 | 3,671 | 2,597 | 2,739 |
| Pre-tax Income | -30,258 | -11,096 | 47,707 | 15,601 | -23,788 |
| Income Tax | -3,177 | 1,199 | 822 | 2,164 | 71 |
| Net Income Continuous | -27,081 | -12,295 | 46,885 | 13,437 | -23,859 |
| Net Income | $-27,081 | $-12,295 | $46,885 | $13,437 | $-23,859 |
| EPS Basic Total Ops | -0.33 | -0.15 | 0.57 | 0.27 | -0.29 |
| EPS Basic Continuous Ops | -0.33 | -0.15 | 0.57 | 0.26 | -0.29 |
| EPS Diluted Total Ops | -0.33 | -0.15 | 0.57 | 0.27 | -0.29 |
| EPS Diluted Continuous Ops | -0.33 | -0.15 | 0.57 | 0.26 | -0.29 |
| EPS Diluted Before Non-Recurring Items | -0.33 | -0.15 | 0.57 | 0.23 | -0.29 |
| EBITDA(a) | $-30,880 | $-13,429 | $46,084 | $15,065 | $-24,424 |